RxDoctor Payments Data

Joe Robinson, MD

Internal Medicine · Macon, GANPI 1679835649

Payments from drug & device makers

$610in general payments, 2019–2025

Across 20 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$143
  • AstraZeneca$138
  • Amgen$82
  • Mannkind Corporation$59
  • Bayer$45
  • Dexcom, Inc.$29
  • plus $115 from 6 others

What the payments were for

  • Food & beverage$55190%
  • Gifts$5910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$67,050
Medicare patients
172
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$251,945
JardianceEmpagliflozin115$105,106
FarxigaDapagliflozin Propanediol65$65,040
EliquisApixaban68$62,760
MounjaroTirzepatide22$27,881
TrulicityDulaglutide14$27,578
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,130
XareltoRivaroxaban29$20,774
Tresiba Flextouch U-100Insulin Degludec36$20,706
Repatha SureclickEvolocumab15$16,017
KerendiaFinerenone22$13,386
LinzessLinaclotide11$13,186
Advair HfaFluticasone Propion/Salmeterol31$9,803
Diclofenac Sodium126$5,823
VascepaIcosapent Ethyl13$5,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$251,945175 claims
AstraZenecaFarxiga, Symbicort$138$69,71785 claims
PfizerEliquis$24$62,76068 claims
GSKTrelegy Ellipta, Shingrix$143$28,30355 claims
BayerKerendia$45$13,38622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →